A first-in-human phase 1 iadademstat clinical study was conducted in relapsed refractory acute leukemia enriched with MLL/KMT2A-rearranged acute myeloid leukemia patients with most having MLL-translocation disease. Here, KMT2A is linked to acute leukemia.